Rates of Ocular Toxicity Are Low Following Immune Checkpoint Inhibition
Immune-related adverse events due to checkpoint inhibitor treatment can affect any organ and may be linked to ocular adverse events
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
Study Updating Meta-analysis Confirms the Deleterious Effect of Systemic Antibiotics on Immune Checkpoint Inhibitor Efficacy
Previously reported findings suggest that systemic antibiotic exposure may alter the efficacy of treatment with an immune checkpoint inhibitor by impacting the intestinal microbiota
The Lung Immune Prognostic Index May Indicate Response to Immune Checkpoint Inhibitors in Patients with MSI-H or dMMR Tumours
Immune checkpoint inhibitor treatment is used for tumours with microsatellite instability high or mismatch repair deficiency but not all of these patients respond
Machine Learning-Based Model Shows Promise for Indicating Response to Immune Checkpoint Inhibition
Not all eligible patients respond to treatment with an immune checkpoint inhibitor
Pleural Effusion Emerges as a Negative Prognostic Factor for Immune Checkpoint Inhibitor Treatment in Patients with Non-Small Cell Lung Cancer
Pleural effusion was associated with worse patient characteristics, poorer survival and higher early death rates
Low Risk of Cardiotoxicity with Immune Checkpoint Inhibitor Monotherapy or Combination Treatment
Life-threatening adverse events have been reported in some patients following immune checkpoint inhibitor treatment for cancer
Front-line Anti-PD1 Treatment Outperforms BRAF/MEK Therapy in BRAFV600-mutant Advanced Melanoma
Data from a propensity-matched survival analysis
Significantly Longer PFS with First-line Pembrolizumab for MSI-H/dMMR mCRC
Pembrolizumab led to significantly longer progression-free survival than chemotherapy in KEYNOTE-177 as first-line treatment for MSI-H/dMMR metastatic colorectal cancer
FDA Approves Pralsetinib for RET-Altered Thyroid Cancers
Evidence for efficacy is based on the results from the ARROW study
FDA Approves Device for Treatment of Osteoid Osteoma in the Extremities
Clinical results support the probable benefit of MR-guided High Intensity Focused Ultrasound system for the ablation of painful osteoid osteoma
First Global Estimates of Cervical Cancer Attributable to HIV
Pooled risk of cervical cancer increased in women living with HIV
FDA Grants Accelerated Approval to Naxitamab for High-Risk Neuroblastoma in Bone or Bone Marrow
Efficacy was evaluated in Study 201 and Study 12-230